nodes	percent_of_prediction	percent_of_DWPC	metapath
Maraviroc—CYP3A4—Vandetanib—thyroid cancer	0.0333	0.508	CbGbCtD
Maraviroc—CYP3A4—Sorafenib—thyroid cancer	0.0201	0.306	CbGbCtD
Maraviroc—CYP3A4—Doxorubicin—thyroid cancer	0.0122	0.186	CbGbCtD
Maraviroc—CCR5—Peptide GPCRs—TSHR—thyroid cancer	0.00858	0.0996	CbGpPWpGaD
Maraviroc—CCR5—HIV Life Cycle—TPR—thyroid cancer	0.00527	0.0612	CbGpPWpGaD
Maraviroc—CCR5—GPCR ligand binding—CALCB—thyroid cancer	0.00445	0.0517	CbGpPWpGaD
Maraviroc—CCR5—HIV Infection—TPR—thyroid cancer	0.00364	0.0423	CbGpPWpGaD
Maraviroc—CCR5—Peptide ligand-binding receptors—SST—thyroid cancer	0.00314	0.0364	CbGpPWpGaD
Maraviroc—CCR5—Class A/1 (Rhodopsin-like receptors)—TSHR—thyroid cancer	0.00271	0.0314	CbGpPWpGaD
Maraviroc—CCR5—G alpha (i) signalling events—SST—thyroid cancer	0.00265	0.0307	CbGpPWpGaD
Maraviroc—CCR5—GPCR downstream signaling—CALCB—thyroid cancer	0.00252	0.0292	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—CALCB—thyroid cancer	0.00228	0.0265	CbGpPWpGaD
Maraviroc—CCR5—Class A/1 (Rhodopsin-like receptors)—SST—thyroid cancer	0.0021	0.0244	CbGpPWpGaD
Maraviroc—CCR5—GPCR ligand binding—TSHR—thyroid cancer	0.00206	0.0239	CbGpPWpGaD
Maraviroc—CCR5—Disease—TRIM24—thyroid cancer	0.00205	0.0238	CbGpPWpGaD
Maraviroc—CYP3A4—Liver X Receptor Pathway—RXRA—thyroid cancer	0.00199	0.0231	CbGpPWpGaD
Maraviroc—CCR5—Disease—CHST14—thyroid cancer	0.00193	0.0224	CbGpPWpGaD
Maraviroc—CCR5—Disease—TRIM33—thyroid cancer	0.00183	0.0212	CbGpPWpGaD
Maraviroc—CCR5—GPCR ligand binding—PTCH1—thyroid cancer	0.00175	0.0203	CbGpPWpGaD
Maraviroc—CCR5—GPCR ligand binding—SST—thyroid cancer	0.0016	0.0186	CbGpPWpGaD
Maraviroc—CCR5—GPCR ligand binding—CALCA—thyroid cancer	0.00154	0.0179	CbGpPWpGaD
Maraviroc—Alopecia—Sorafenib—thyroid cancer	0.00149	0.00176	CcSEcCtD
Maraviroc—Mental disorder—Sorafenib—thyroid cancer	0.00148	0.00175	CcSEcCtD
Maraviroc—Otitis media—Doxorubicin—thyroid cancer	0.00148	0.00174	CcSEcCtD
Maraviroc—Erythema—Sorafenib—thyroid cancer	0.00147	0.00173	CcSEcCtD
Maraviroc—Malnutrition—Sorafenib—thyroid cancer	0.00147	0.00173	CcSEcCtD
Maraviroc—Neoplasm malignant—Epirubicin—thyroid cancer	0.00146	0.00172	CcSEcCtD
Maraviroc—Gastrointestinal pain—Vandetanib—thyroid cancer	0.00146	0.00172	CcSEcCtD
Maraviroc—Jaundice cholestatic—Epirubicin—thyroid cancer	0.00142	0.00167	CcSEcCtD
Maraviroc—Body temperature increased—Vandetanib—thyroid cancer	0.00141	0.00166	CcSEcCtD
Maraviroc—Abdominal pain—Vandetanib—thyroid cancer	0.00141	0.00166	CcSEcCtD
Maraviroc—Rectal haemorrhage—Epirubicin—thyroid cancer	0.00138	0.00162	CcSEcCtD
Maraviroc—Hyperbilirubinaemia—Epirubicin—thyroid cancer	0.00137	0.00161	CcSEcCtD
Maraviroc—Anaemia—Sorafenib—thyroid cancer	0.00136	0.0016	CcSEcCtD
Maraviroc—Oliguria—Epirubicin—thyroid cancer	0.00135	0.00159	CcSEcCtD
Maraviroc—Herpes simplex—Epirubicin—thyroid cancer	0.00135	0.00159	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—CALCB—thyroid cancer	0.00135	0.0157	CbGpPWpGaD
Maraviroc—Neoplasm malignant—Doxorubicin—thyroid cancer	0.00135	0.00159	CcSEcCtD
Maraviroc—Syncope—Sorafenib—thyroid cancer	0.00132	0.00156	CcSEcCtD
Maraviroc—Leukopenia—Sorafenib—thyroid cancer	0.00132	0.00155	CcSEcCtD
Maraviroc—Ulcer—Epirubicin—thyroid cancer	0.00132	0.00155	CcSEcCtD
Maraviroc—Jaundice cholestatic—Doxorubicin—thyroid cancer	0.00131	0.00154	CcSEcCtD
Maraviroc—CCR5—TCR Signaling Pathway—HRAS—thyroid cancer	0.0013	0.0151	CbGpPWpGaD
Maraviroc—Loss of consciousness—Sorafenib—thyroid cancer	0.00129	0.00152	CcSEcCtD
Maraviroc—Cough—Sorafenib—thyroid cancer	0.00128	0.00151	CcSEcCtD
Maraviroc—Inflammation—Epirubicin—thyroid cancer	0.00128	0.00151	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—TRIM33—thyroid cancer	0.00128	0.0148	CbGpPWpGaD
Maraviroc—Asthenia—Vandetanib—thyroid cancer	0.00128	0.00151	CcSEcCtD
Maraviroc—Rectal haemorrhage—Doxorubicin—thyroid cancer	0.00127	0.0015	CcSEcCtD
Maraviroc—Hyperbilirubinaemia—Doxorubicin—thyroid cancer	0.00127	0.00149	CcSEcCtD
Maraviroc—Pruritus—Vandetanib—thyroid cancer	0.00126	0.00148	CcSEcCtD
Maraviroc—Myalgia—Sorafenib—thyroid cancer	0.00125	0.00148	CcSEcCtD
Maraviroc—Oliguria—Doxorubicin—thyroid cancer	0.00125	0.00147	CcSEcCtD
Maraviroc—Herpes simplex—Doxorubicin—thyroid cancer	0.00125	0.00147	CcSEcCtD
Maraviroc—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—thyroid cancer	0.00124	0.00147	CcSEcCtD
Maraviroc—CCR5—Disease—TCF7L1—thyroid cancer	0.00122	0.0141	CbGpPWpGaD
Maraviroc—Diarrhoea—Vandetanib—thyroid cancer	0.00122	0.00144	CcSEcCtD
Maraviroc—Ulcer—Doxorubicin—thyroid cancer	0.00122	0.00143	CcSEcCtD
Maraviroc—Influenza like illness—Epirubicin—thyroid cancer	0.00121	0.00142	CcSEcCtD
Maraviroc—Colitis—Epirubicin—thyroid cancer	0.00119	0.00141	CcSEcCtD
Maraviroc—CYP3A4—Farnesoid X Receptor  Pathway—RXRA—thyroid cancer	0.00119	0.0139	CbGpPWpGaD
Maraviroc—Infection—Sorafenib—thyroid cancer	0.00119	0.00141	CcSEcCtD
Maraviroc—Inflammation—Doxorubicin—thyroid cancer	0.00119	0.0014	CcSEcCtD
Maraviroc—Shock—Sorafenib—thyroid cancer	0.00118	0.00139	CcSEcCtD
Maraviroc—Nervous system disorder—Sorafenib—thyroid cancer	0.00118	0.00139	CcSEcCtD
Maraviroc—Dizziness—Vandetanib—thyroid cancer	0.00118	0.00139	CcSEcCtD
Maraviroc—Skin disorder—Sorafenib—thyroid cancer	0.00117	0.00138	CcSEcCtD
Maraviroc—CCR5—GPCR downstream signaling—TSHR—thyroid cancer	0.00116	0.0135	CbGpPWpGaD
Maraviroc—CCR5—TCR Signaling Pathway—AKT1—thyroid cancer	0.00115	0.0134	CbGpPWpGaD
Maraviroc—Anorexia—Sorafenib—thyroid cancer	0.00114	0.00135	CcSEcCtD
Maraviroc—Vomiting—Vandetanib—thyroid cancer	0.00113	0.00133	CcSEcCtD
Maraviroc—Neoplasm—Epirubicin—thyroid cancer	0.00112	0.00133	CcSEcCtD
Maraviroc—Rash—Vandetanib—thyroid cancer	0.00112	0.00132	CcSEcCtD
Maraviroc—Dermatitis—Vandetanib—thyroid cancer	0.00112	0.00132	CcSEcCtD
Maraviroc—Influenza like illness—Doxorubicin—thyroid cancer	0.00112	0.00132	CcSEcCtD
Maraviroc—Headache—Vandetanib—thyroid cancer	0.00112	0.00131	CcSEcCtD
Maraviroc—Colitis—Doxorubicin—thyroid cancer	0.00111	0.0013	CcSEcCtD
Maraviroc—Musculoskeletal discomfort—Sorafenib—thyroid cancer	0.00109	0.00129	CcSEcCtD
Maraviroc—Lymphadenopathy—Epirubicin—thyroid cancer	0.00106	0.00125	CcSEcCtD
Maraviroc—CCR5—Signaling by GPCR—TSHR—thyroid cancer	0.00106	0.0123	CbGpPWpGaD
Maraviroc—Nausea—Vandetanib—thyroid cancer	0.00106	0.00125	CcSEcCtD
Maraviroc—Decreased appetite—Sorafenib—thyroid cancer	0.00104	0.00123	CcSEcCtD
Maraviroc—Neoplasm—Doxorubicin—thyroid cancer	0.00104	0.00123	CcSEcCtD
Maraviroc—CCR5—Signaling by GPCR—PRKAR1A—thyroid cancer	0.00104	0.0121	CbGpPWpGaD
Maraviroc—Blood alkaline phosphatase increased—Epirubicin—thyroid cancer	0.00104	0.00122	CcSEcCtD
Maraviroc—Diabetes mellitus—Epirubicin—thyroid cancer	0.00104	0.00122	CcSEcCtD
Maraviroc—Gastrointestinal disorder—Sorafenib—thyroid cancer	0.00104	0.00122	CcSEcCtD
Maraviroc—Fatigue—Sorafenib—thyroid cancer	0.00104	0.00122	CcSEcCtD
Maraviroc—Pain—Sorafenib—thyroid cancer	0.00103	0.00121	CcSEcCtD
Maraviroc—Constipation—Sorafenib—thyroid cancer	0.00103	0.00121	CcSEcCtD
Maraviroc—Vascular purpura—Epirubicin—thyroid cancer	0.00101	0.00119	CcSEcCtD
Maraviroc—Hepatic failure—Epirubicin—thyroid cancer	0.001	0.00118	CcSEcCtD
Maraviroc—Eczema—Epirubicin—thyroid cancer	0.001	0.00118	CcSEcCtD
Maraviroc—Gastrointestinal pain—Sorafenib—thyroid cancer	0.000982	0.00116	CcSEcCtD
Maraviroc—Lymphadenopathy—Doxorubicin—thyroid cancer	0.000979	0.00115	CcSEcCtD
Maraviroc—Renal failure acute—Epirubicin—thyroid cancer	0.000978	0.00115	CcSEcCtD
Maraviroc—Blood alkaline phosphatase increased—Doxorubicin—thyroid cancer	0.000961	0.00113	CcSEcCtD
Maraviroc—Diabetes mellitus—Doxorubicin—thyroid cancer	0.000961	0.00113	CcSEcCtD
Maraviroc—Dermatitis exfoliative—Epirubicin—thyroid cancer	0.000957	0.00113	CcSEcCtD
Maraviroc—Abdominal pain—Sorafenib—thyroid cancer	0.000949	0.00112	CcSEcCtD
Maraviroc—Body temperature increased—Sorafenib—thyroid cancer	0.000949	0.00112	CcSEcCtD
Maraviroc—Purpura—Epirubicin—thyroid cancer	0.000937	0.0011	CcSEcCtD
Maraviroc—Vascular purpura—Doxorubicin—thyroid cancer	0.000934	0.0011	CcSEcCtD
Maraviroc—Hepatic failure—Doxorubicin—thyroid cancer	0.00093	0.0011	CcSEcCtD
Maraviroc—Eczema—Doxorubicin—thyroid cancer	0.00093	0.0011	CcSEcCtD
Maraviroc—Cerebrovascular accident—Epirubicin—thyroid cancer	0.000922	0.00109	CcSEcCtD
Maraviroc—CCR5—GPCR downstream signaling—SST—thyroid cancer	0.000906	0.0105	CbGpPWpGaD
Maraviroc—Renal failure acute—Doxorubicin—thyroid cancer	0.000905	0.00107	CcSEcCtD
Maraviroc—CCR5—Signaling by GPCR—PTCH1—thyroid cancer	0.000899	0.0104	CbGpPWpGaD
Maraviroc—CCR5—Disease—TPR—thyroid cancer	0.000892	0.0104	CbGpPWpGaD
Maraviroc—Dermatitis exfoliative—Doxorubicin—thyroid cancer	0.000886	0.00104	CcSEcCtD
Maraviroc—Hypersensitivity—Sorafenib—thyroid cancer	0.000885	0.00104	CcSEcCtD
Maraviroc—CCR5—Disease—PRKAR1A—thyroid cancer	0.000878	0.0102	CbGpPWpGaD
Maraviroc—CCR5—GPCR downstream signaling—CALCA—thyroid cancer	0.000872	0.0101	CbGpPWpGaD
Maraviroc—Purpura—Doxorubicin—thyroid cancer	0.000867	0.00102	CcSEcCtD
Maraviroc—Asthenia—Sorafenib—thyroid cancer	0.000862	0.00102	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—TCF7L1—thyroid cancer	0.000854	0.00991	CbGpPWpGaD
Maraviroc—Cerebrovascular accident—Doxorubicin—thyroid cancer	0.000853	0.00101	CcSEcCtD
Maraviroc—Pruritus—Sorafenib—thyroid cancer	0.00085	0.001	CcSEcCtD
Maraviroc—CCR5—Disease—MEN1—thyroid cancer	0.000839	0.00974	CbGpPWpGaD
Maraviroc—Abdominal pain upper—Epirubicin—thyroid cancer	0.000825	0.000972	CcSEcCtD
Maraviroc—Orthostatic hypotension—Epirubicin—thyroid cancer	0.000825	0.000972	CcSEcCtD
Maraviroc—CCR5—Signaling by GPCR—SST—thyroid cancer	0.000823	0.00955	CbGpPWpGaD
Maraviroc—Diarrhoea—Sorafenib—thyroid cancer	0.000822	0.000969	CcSEcCtD
Maraviroc—Breast disorder—Epirubicin—thyroid cancer	0.000816	0.000962	CcSEcCtD
Maraviroc—Toxic epidermal necrolysis—Epirubicin—thyroid cancer	0.000813	0.000959	CcSEcCtD
Maraviroc—Aspartate aminotransferase increased—Epirubicin—thyroid cancer	0.000813	0.000959	CcSEcCtD
Maraviroc—Nasopharyngitis—Epirubicin—thyroid cancer	0.000808	0.000952	CcSEcCtD
Maraviroc—Alanine aminotransferase increased—Epirubicin—thyroid cancer	0.000797	0.000939	CcSEcCtD
Maraviroc—Dizziness—Sorafenib—thyroid cancer	0.000794	0.000936	CcSEcCtD
Maraviroc—CCR5—Signaling by GPCR—CALCA—thyroid cancer	0.000792	0.00919	CbGpPWpGaD
Maraviroc—CYP3A4—Constitutive Androstane Receptor Pathway—RXRA—thyroid cancer	0.000787	0.00913	CbGpPWpGaD
Maraviroc—Abdominal distension—Epirubicin—thyroid cancer	0.000786	0.000926	CcSEcCtD
Maraviroc—Influenza—Epirubicin—thyroid cancer	0.000781	0.00092	CcSEcCtD
Maraviroc—Eosinophilia—Epirubicin—thyroid cancer	0.000773	0.000911	CcSEcCtD
Maraviroc—Pancreatitis—Epirubicin—thyroid cancer	0.000765	0.000902	CcSEcCtD
Maraviroc—Vomiting—Sorafenib—thyroid cancer	0.000764	0.0009	CcSEcCtD
Maraviroc—Abdominal pain upper—Doxorubicin—thyroid cancer	0.000763	0.0009	CcSEcCtD
Maraviroc—Orthostatic hypotension—Doxorubicin—thyroid cancer	0.000763	0.0009	CcSEcCtD
Maraviroc—Angina pectoris—Epirubicin—thyroid cancer	0.00076	0.000896	CcSEcCtD
Maraviroc—Rash—Sorafenib—thyroid cancer	0.000757	0.000893	CcSEcCtD
Maraviroc—Dermatitis—Sorafenib—thyroid cancer	0.000757	0.000892	CcSEcCtD
Maraviroc—Breast disorder—Doxorubicin—thyroid cancer	0.000755	0.00089	CcSEcCtD
Maraviroc—Toxic epidermal necrolysis—Doxorubicin—thyroid cancer	0.000752	0.000887	CcSEcCtD
Maraviroc—Aspartate aminotransferase increased—Doxorubicin—thyroid cancer	0.000752	0.000887	CcSEcCtD
Maraviroc—Headache—Sorafenib—thyroid cancer	0.000752	0.000887	CcSEcCtD
Maraviroc—Bronchitis—Epirubicin—thyroid cancer	0.000751	0.000885	CcSEcCtD
Maraviroc—Nasopharyngitis—Doxorubicin—thyroid cancer	0.000747	0.000881	CcSEcCtD
Maraviroc—Pancytopenia—Epirubicin—thyroid cancer	0.000741	0.000874	CcSEcCtD
Maraviroc—Alanine aminotransferase increased—Doxorubicin—thyroid cancer	0.000737	0.000869	CcSEcCtD
Maraviroc—Neutropenia—Epirubicin—thyroid cancer	0.00073	0.00086	CcSEcCtD
Maraviroc—Abdominal distension—Doxorubicin—thyroid cancer	0.000727	0.000857	CcSEcCtD
Maraviroc—Upper respiratory tract infection—Epirubicin—thyroid cancer	0.000725	0.000855	CcSEcCtD
Maraviroc—Influenza—Doxorubicin—thyroid cancer	0.000722	0.000851	CcSEcCtD
Maraviroc—CCR5—Signaling by GPCR—CDK1—thyroid cancer	0.000717	0.00832	CbGpPWpGaD
Maraviroc—Eosinophilia—Doxorubicin—thyroid cancer	0.000715	0.000843	CcSEcCtD
Maraviroc—Nausea—Sorafenib—thyroid cancer	0.000713	0.000841	CcSEcCtD
Maraviroc—Pancreatitis—Doxorubicin—thyroid cancer	0.000708	0.000835	CcSEcCtD
Maraviroc—Angina pectoris—Doxorubicin—thyroid cancer	0.000704	0.000829	CcSEcCtD
Maraviroc—Pneumonia—Epirubicin—thyroid cancer	0.0007	0.000825	CcSEcCtD
Maraviroc—Infestation NOS—Epirubicin—thyroid cancer	0.000696	0.00082	CcSEcCtD
Maraviroc—Infestation—Epirubicin—thyroid cancer	0.000696	0.00082	CcSEcCtD
Maraviroc—Bronchitis—Doxorubicin—thyroid cancer	0.000695	0.000819	CcSEcCtD
Maraviroc—CYP3A4—Metapathway biotransformation—CHST14—thyroid cancer	0.000694	0.00805	CbGpPWpGaD
Maraviroc—Stevens-Johnson syndrome—Epirubicin—thyroid cancer	0.00069	0.000813	CcSEcCtD
Maraviroc—Pancytopenia—Doxorubicin—thyroid cancer	0.000686	0.000809	CcSEcCtD
Maraviroc—Renal failure—Epirubicin—thyroid cancer	0.000684	0.000806	CcSEcCtD
Maraviroc—Neuropathy peripheral—Epirubicin—thyroid cancer	0.000682	0.000804	CcSEcCtD
Maraviroc—Stomatitis—Epirubicin—thyroid cancer	0.000678	0.0008	CcSEcCtD
Maraviroc—Jaundice—Epirubicin—thyroid cancer	0.000678	0.0008	CcSEcCtD
Maraviroc—Conjunctivitis—Epirubicin—thyroid cancer	0.000676	0.000797	CcSEcCtD
Maraviroc—Neutropenia—Doxorubicin—thyroid cancer	0.000675	0.000796	CcSEcCtD
Maraviroc—Upper respiratory tract infection—Doxorubicin—thyroid cancer	0.000671	0.000791	CcSEcCtD
Maraviroc—CCR5—Disease—CALCA—thyroid cancer	0.000668	0.00775	CbGpPWpGaD
Maraviroc—Hepatobiliary disease—Epirubicin—thyroid cancer	0.000658	0.000776	CcSEcCtD
Maraviroc—Sinusitis—Epirubicin—thyroid cancer	0.000653	0.00077	CcSEcCtD
Maraviroc—Agranulocytosis—Epirubicin—thyroid cancer	0.000649	0.000766	CcSEcCtD
Maraviroc—Pneumonia—Doxorubicin—thyroid cancer	0.000648	0.000764	CcSEcCtD
Maraviroc—Infestation NOS—Doxorubicin—thyroid cancer	0.000644	0.000759	CcSEcCtD
Maraviroc—Infestation—Doxorubicin—thyroid cancer	0.000644	0.000759	CcSEcCtD
Maraviroc—Stevens-Johnson syndrome—Doxorubicin—thyroid cancer	0.000638	0.000753	CcSEcCtD
Maraviroc—Renal failure—Doxorubicin—thyroid cancer	0.000633	0.000746	CcSEcCtD
Maraviroc—Neuropathy peripheral—Doxorubicin—thyroid cancer	0.000631	0.000744	CcSEcCtD
Maraviroc—Stomatitis—Doxorubicin—thyroid cancer	0.000628	0.00074	CcSEcCtD
Maraviroc—Jaundice—Doxorubicin—thyroid cancer	0.000628	0.00074	CcSEcCtD
Maraviroc—Rhinitis—Epirubicin—thyroid cancer	0.000626	0.000738	CcSEcCtD
Maraviroc—Conjunctivitis—Doxorubicin—thyroid cancer	0.000626	0.000738	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—TSHR—thyroid cancer	0.000625	0.00725	CbGpPWpGaD
Maraviroc—Pharyngitis—Epirubicin—thyroid cancer	0.00062	0.000731	CcSEcCtD
Maraviroc—Urinary tract disorder—Epirubicin—thyroid cancer	0.000617	0.000727	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—PRKAR1A—thyroid cancer	0.000615	0.00713	CbGpPWpGaD
Maraviroc—Connective tissue disorder—Epirubicin—thyroid cancer	0.000614	0.000724	CcSEcCtD
Maraviroc—Urethral disorder—Epirubicin—thyroid cancer	0.000612	0.000722	CcSEcCtD
Maraviroc—Hepatobiliary disease—Doxorubicin—thyroid cancer	0.000609	0.000718	CcSEcCtD
Maraviroc—CCR5—Disease—CDK1—thyroid cancer	0.000605	0.00702	CbGpPWpGaD
Maraviroc—Sinusitis—Doxorubicin—thyroid cancer	0.000604	0.000712	CcSEcCtD
Maraviroc—Agranulocytosis—Doxorubicin—thyroid cancer	0.000601	0.000708	CcSEcCtD
Maraviroc—Erythema multiforme—Epirubicin—thyroid cancer	0.000591	0.000696	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—MEN1—thyroid cancer	0.000587	0.00682	CbGpPWpGaD
Maraviroc—Eye disorder—Epirubicin—thyroid cancer	0.000584	0.000688	CcSEcCtD
Maraviroc—Cardiac disorder—Epirubicin—thyroid cancer	0.00058	0.000684	CcSEcCtD
Maraviroc—Rhinitis—Doxorubicin—thyroid cancer	0.00058	0.000683	CcSEcCtD
Maraviroc—Pharyngitis—Doxorubicin—thyroid cancer	0.000574	0.000676	CcSEcCtD
Maraviroc—Urinary tract disorder—Doxorubicin—thyroid cancer	0.000571	0.000673	CcSEcCtD
Maraviroc—Connective tissue disorder—Doxorubicin—thyroid cancer	0.000568	0.00067	CcSEcCtD
Maraviroc—Angiopathy—Epirubicin—thyroid cancer	0.000567	0.000668	CcSEcCtD
Maraviroc—Urethral disorder—Doxorubicin—thyroid cancer	0.000567	0.000668	CcSEcCtD
Maraviroc—Mediastinal disorder—Epirubicin—thyroid cancer	0.000563	0.000664	CcSEcCtD
Maraviroc—Alopecia—Epirubicin—thyroid cancer	0.000552	0.000651	CcSEcCtD
Maraviroc—Mental disorder—Epirubicin—thyroid cancer	0.000547	0.000645	CcSEcCtD
Maraviroc—Erythema multiforme—Doxorubicin—thyroid cancer	0.000547	0.000644	CcSEcCtD
Maraviroc—Erythema—Epirubicin—thyroid cancer	0.000544	0.000641	CcSEcCtD
Maraviroc—Malnutrition—Epirubicin—thyroid cancer	0.000544	0.000641	CcSEcCtD
Maraviroc—Eye disorder—Doxorubicin—thyroid cancer	0.00054	0.000637	CcSEcCtD
Maraviroc—Cardiac disorder—Doxorubicin—thyroid cancer	0.000536	0.000632	CcSEcCtD
Maraviroc—Flatulence—Epirubicin—thyroid cancer	0.000536	0.000632	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—PTCH1—thyroid cancer	0.000531	0.00617	CbGpPWpGaD
Maraviroc—Angiopathy—Doxorubicin—thyroid cancer	0.000524	0.000618	CcSEcCtD
Maraviroc—Mediastinal disorder—Doxorubicin—thyroid cancer	0.000521	0.000614	CcSEcCtD
Maraviroc—Alopecia—Doxorubicin—thyroid cancer	0.000511	0.000602	CcSEcCtD
Maraviroc—Mental disorder—Doxorubicin—thyroid cancer	0.000506	0.000597	CcSEcCtD
Maraviroc—Malnutrition—Doxorubicin—thyroid cancer	0.000503	0.000593	CcSEcCtD
Maraviroc—Erythema—Doxorubicin—thyroid cancer	0.000503	0.000593	CcSEcCtD
Maraviroc—Anaemia—Epirubicin—thyroid cancer	0.000503	0.000593	CcSEcCtD
Maraviroc—Flatulence—Doxorubicin—thyroid cancer	0.000496	0.000585	CcSEcCtD
Maraviroc—Syncope—Epirubicin—thyroid cancer	0.000488	0.000575	CcSEcCtD
Maraviroc—Leukopenia—Epirubicin—thyroid cancer	0.000487	0.000574	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—SST—thyroid cancer	0.000486	0.00564	CbGpPWpGaD
Maraviroc—CCR5—Disease—NRG1—thyroid cancer	0.000485	0.00563	CbGpPWpGaD
Maraviroc—Loss of consciousness—Epirubicin—thyroid cancer	0.000478	0.000564	CcSEcCtD
Maraviroc—CYP3A4—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	0.000476	0.00552	CbGpPWpGaD
Maraviroc—Cough—Epirubicin—thyroid cancer	0.000475	0.000559	CcSEcCtD
Maraviroc—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—thyroid cancer	0.000473	0.00549	CbGpPWpGaD
Maraviroc—Convulsion—Epirubicin—thyroid cancer	0.000471	0.000556	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—CALCA—thyroid cancer	0.000468	0.00543	CbGpPWpGaD
Maraviroc—Anaemia—Doxorubicin—thyroid cancer	0.000465	0.000548	CcSEcCtD
Maraviroc—Myalgia—Epirubicin—thyroid cancer	0.000463	0.000546	CcSEcCtD
Maraviroc—Anxiety—Epirubicin—thyroid cancer	0.000461	0.000544	CcSEcCtD
Maraviroc—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—thyroid cancer	0.00046	0.000542	CcSEcCtD
Maraviroc—Discomfort—Epirubicin—thyroid cancer	0.000457	0.000539	CcSEcCtD
Maraviroc—Syncope—Doxorubicin—thyroid cancer	0.000451	0.000532	CcSEcCtD
Maraviroc—Leukopenia—Doxorubicin—thyroid cancer	0.00045	0.000531	CcSEcCtD
Maraviroc—Oedema—Epirubicin—thyroid cancer	0.000444	0.000523	CcSEcCtD
Maraviroc—Loss of consciousness—Doxorubicin—thyroid cancer	0.000442	0.000521	CcSEcCtD
Maraviroc—Infection—Epirubicin—thyroid cancer	0.000441	0.00052	CcSEcCtD
Maraviroc—Cough—Doxorubicin—thyroid cancer	0.000439	0.000518	CcSEcCtD
Maraviroc—Shock—Epirubicin—thyroid cancer	0.000437	0.000515	CcSEcCtD
Maraviroc—Convulsion—Doxorubicin—thyroid cancer	0.000436	0.000514	CcSEcCtD
Maraviroc—CCR5—Disease—TERT—thyroid cancer	0.000436	0.00506	CbGpPWpGaD
Maraviroc—Nervous system disorder—Epirubicin—thyroid cancer	0.000435	0.000513	CcSEcCtD
Maraviroc—Skin disorder—Epirubicin—thyroid cancer	0.000431	0.000508	CcSEcCtD
Maraviroc—Myalgia—Doxorubicin—thyroid cancer	0.000428	0.000505	CcSEcCtD
Maraviroc—Anxiety—Doxorubicin—thyroid cancer	0.000427	0.000503	CcSEcCtD
Maraviroc—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—thyroid cancer	0.000425	0.000502	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—CDK1—thyroid cancer	0.000423	0.00491	CbGpPWpGaD
Maraviroc—Discomfort—Doxorubicin—thyroid cancer	0.000423	0.000499	CcSEcCtD
Maraviroc—Anorexia—Epirubicin—thyroid cancer	0.000423	0.000499	CcSEcCtD
Maraviroc—CCR5—Disease—HIF1A—thyroid cancer	0.000417	0.00484	CbGpPWpGaD
Maraviroc—Oedema—Doxorubicin—thyroid cancer	0.000411	0.000484	CcSEcCtD
Maraviroc—Infection—Doxorubicin—thyroid cancer	0.000408	0.000481	CcSEcCtD
Maraviroc—Musculoskeletal discomfort—Epirubicin—thyroid cancer	0.000404	0.000477	CcSEcCtD
Maraviroc—Shock—Doxorubicin—thyroid cancer	0.000404	0.000476	CcSEcCtD
Maraviroc—Nervous system disorder—Doxorubicin—thyroid cancer	0.000403	0.000475	CcSEcCtD
Maraviroc—Insomnia—Epirubicin—thyroid cancer	0.000401	0.000473	CcSEcCtD
Maraviroc—Skin disorder—Doxorubicin—thyroid cancer	0.000399	0.00047	CcSEcCtD
Maraviroc—Paraesthesia—Epirubicin—thyroid cancer	0.000399	0.00047	CcSEcCtD
Maraviroc—Anorexia—Doxorubicin—thyroid cancer	0.000391	0.000462	CcSEcCtD
Maraviroc—Decreased appetite—Epirubicin—thyroid cancer	0.000386	0.000455	CcSEcCtD
Maraviroc—CYP3A4—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	0.000386	0.00448	CbGpPWpGaD
Maraviroc—Gastrointestinal disorder—Epirubicin—thyroid cancer	0.000383	0.000452	CcSEcCtD
Maraviroc—Fatigue—Epirubicin—thyroid cancer	0.000383	0.000451	CcSEcCtD
Maraviroc—Pain—Epirubicin—thyroid cancer	0.00038	0.000447	CcSEcCtD
Maraviroc—Constipation—Epirubicin—thyroid cancer	0.00038	0.000447	CcSEcCtD
Maraviroc—Musculoskeletal discomfort—Doxorubicin—thyroid cancer	0.000374	0.000441	CcSEcCtD
Maraviroc—Insomnia—Doxorubicin—thyroid cancer	0.000371	0.000438	CcSEcCtD
Maraviroc—Paraesthesia—Doxorubicin—thyroid cancer	0.000369	0.000435	CcSEcCtD
Maraviroc—Gastrointestinal pain—Epirubicin—thyroid cancer	0.000363	0.000428	CcSEcCtD
Maraviroc—Decreased appetite—Doxorubicin—thyroid cancer	0.000357	0.000421	CcSEcCtD
Maraviroc—Gastrointestinal disorder—Doxorubicin—thyroid cancer	0.000355	0.000418	CcSEcCtD
Maraviroc—Fatigue—Doxorubicin—thyroid cancer	0.000354	0.000417	CcSEcCtD
Maraviroc—Constipation—Doxorubicin—thyroid cancer	0.000351	0.000414	CcSEcCtD
Maraviroc—Pain—Doxorubicin—thyroid cancer	0.000351	0.000414	CcSEcCtD
Maraviroc—Abdominal pain—Epirubicin—thyroid cancer	0.000351	0.000414	CcSEcCtD
Maraviroc—Body temperature increased—Epirubicin—thyroid cancer	0.000351	0.000414	CcSEcCtD
Maraviroc—CCR5—Disease—BRAF—thyroid cancer	0.000345	0.004	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—NRG1—thyroid cancer	0.00034	0.00394	CbGpPWpGaD
Maraviroc—Gastrointestinal pain—Doxorubicin—thyroid cancer	0.000336	0.000396	CcSEcCtD
Maraviroc—Hypersensitivity—Epirubicin—thyroid cancer	0.000327	0.000386	CcSEcCtD
Maraviroc—Abdominal pain—Doxorubicin—thyroid cancer	0.000325	0.000383	CcSEcCtD
Maraviroc—Body temperature increased—Doxorubicin—thyroid cancer	0.000325	0.000383	CcSEcCtD
Maraviroc—Asthenia—Epirubicin—thyroid cancer	0.000318	0.000375	CcSEcCtD
Maraviroc—Pruritus—Epirubicin—thyroid cancer	0.000314	0.00037	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—TERT—thyroid cancer	0.000305	0.00354	CbGpPWpGaD
Maraviroc—Diarrhoea—Epirubicin—thyroid cancer	0.000304	0.000358	CcSEcCtD
Maraviroc—Hypersensitivity—Doxorubicin—thyroid cancer	0.000303	0.000357	CcSEcCtD
Maraviroc—Asthenia—Doxorubicin—thyroid cancer	0.000295	0.000347	CcSEcCtD
Maraviroc—Dizziness—Epirubicin—thyroid cancer	0.000294	0.000346	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—HIF1A—thyroid cancer	0.000292	0.00339	CbGpPWpGaD
Maraviroc—Pruritus—Doxorubicin—thyroid cancer	0.000291	0.000343	CcSEcCtD
Maraviroc—Vomiting—Epirubicin—thyroid cancer	0.000282	0.000333	CcSEcCtD
Maraviroc—Diarrhoea—Doxorubicin—thyroid cancer	0.000281	0.000331	CcSEcCtD
Maraviroc—Rash—Epirubicin—thyroid cancer	0.00028	0.00033	CcSEcCtD
Maraviroc—Dermatitis—Epirubicin—thyroid cancer	0.00028	0.00033	CcSEcCtD
Maraviroc—CCR5—Disease—PTGS2—thyroid cancer	0.000279	0.00323	CbGpPWpGaD
Maraviroc—Headache—Epirubicin—thyroid cancer	0.000278	0.000328	CcSEcCtD
Maraviroc—Dizziness—Doxorubicin—thyroid cancer	0.000272	0.00032	CcSEcCtD
Maraviroc—Nausea—Epirubicin—thyroid cancer	0.000264	0.000311	CcSEcCtD
Maraviroc—Vomiting—Doxorubicin—thyroid cancer	0.000261	0.000308	CcSEcCtD
Maraviroc—Rash—Doxorubicin—thyroid cancer	0.000259	0.000305	CcSEcCtD
Maraviroc—Dermatitis—Doxorubicin—thyroid cancer	0.000259	0.000305	CcSEcCtD
Maraviroc—Headache—Doxorubicin—thyroid cancer	0.000257	0.000303	CcSEcCtD
Maraviroc—CCR5—Signaling by GPCR—NRAS—thyroid cancer	0.000257	0.00298	CbGpPWpGaD
Maraviroc—Nausea—Doxorubicin—thyroid cancer	0.000244	0.000288	CcSEcCtD
Maraviroc—CCR5—Disease—PTEN—thyroid cancer	0.000243	0.00282	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—BRAF—thyroid cancer	0.000242	0.0028	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—KRAS—thyroid cancer	0.000221	0.00257	CbGpPWpGaD
Maraviroc—CCR5—Disease—NRAS—thyroid cancer	0.000217	0.00252	CbGpPWpGaD
Maraviroc—CYP3A4—Biological oxidations—RXRA—thyroid cancer	0.000205	0.00238	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—HRAS—thyroid cancer	0.000188	0.00218	CbGpPWpGaD
Maraviroc—CCR5—Disease—KRAS—thyroid cancer	0.000187	0.00217	CbGpPWpGaD
Maraviroc—CCR5—GPCR downstream signaling—AKT1—thyroid cancer	0.000183	0.00212	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—CCND1—thyroid cancer	0.000176	0.00205	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—PTEN—thyroid cancer	0.00017	0.00198	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—AKT1—thyroid cancer	0.000166	0.00193	CbGpPWpGaD
Maraviroc—CCR5—Disease—HRAS—thyroid cancer	0.000159	0.00184	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—NRAS—thyroid cancer	0.000152	0.00176	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—MINPP1—thyroid cancer	0.00015	0.00175	CbGpPWpGaD
Maraviroc—CCR5—Disease—AKT1—thyroid cancer	0.00014	0.00163	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—KRAS—thyroid cancer	0.000131	0.00152	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—NDUFA13—thyroid cancer	0.000128	0.00148	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—CHST14—thyroid cancer	0.00012	0.0014	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—TP53—thyroid cancer	0.000116	0.00135	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—HRAS—thyroid cancer	0.000111	0.00129	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—AKT1—thyroid cancer	9.81e-05	0.00114	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—HPGD—thyroid cancer	9.7e-05	0.00113	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—TPR—thyroid cancer	5.57e-05	0.000646	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—PRKAR1A—thyroid cancer	5.48e-05	0.000636	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—SLC5A5—thyroid cancer	4.17e-05	0.000484	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—RXRA—thyroid cancer	3.5e-05	0.000407	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—PPARG—thyroid cancer	2.21e-05	0.000257	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—PTGS2—thyroid cancer	1.74e-05	0.000202	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—PTEN—thyroid cancer	1.52e-05	0.000176	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—AKT1—thyroid cancer	8.74e-06	0.000101	CbGpPWpGaD
